Mihaila Raluca Ioana, Gheorghe Adelina Silvana, Zob Daniela Luminita, Stanculeanu Dana
Oncology Department, University of Medicine and Pharmacy, Bucharest, ROU.
Medical Oncology Department I, Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROU.
Cureus. 2024 Nov 21;16(11):e74194. doi: 10.7759/cureus.74194. eCollection 2024 Nov.
The correlation between tumor-infiltrating lymphocytes (TILs) and immunotherapy responses is an evolving field with significant clinical implications. Immunotherapy has revolutionized antineoplastic therapies, offering promising results for patients diagnosed with solid tumors. Integrating biomarkers, refining imaging techniques, and developing non-invasive methods may enhance personalized medicine, optimizing treatment strategies while minimizing adverse effects. In our study, we conducted a retrospective analysis to assess the practicality of utilizing the predictive value of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) correlating the response to immunotherapy in patients with solid tumors, comprehensively navigating through currently available data. Continued research efforts and collaboration between scientists and clinicians are essential to unlock the full potential of these biomarkers and advance the field of immunotherapy in solid tumors.
肿瘤浸润淋巴细胞(TILs)与免疫治疗反应之间的相关性是一个不断发展的领域,具有重大的临床意义。免疫疗法彻底改变了抗肿瘤治疗方法,为被诊断患有实体瘤的患者带来了有希望的结果。整合生物标志物、改进成像技术以及开发非侵入性方法可能会增强个性化医疗,优化治疗策略同时将副作用降至最低。在我们的研究中,我们进行了一项回顾性分析,以评估利用肿瘤微环境(TME)中肿瘤浸润淋巴细胞(TILs)的预测价值与实体瘤患者免疫治疗反应之间相关性的实用性,全面梳理当前可得的数据。科学家和临床医生持续的研究努力与合作对于释放这些生物标志物的全部潜力以及推动实体瘤免疫治疗领域的发展至关重要。